Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women

被引：0
|
作者：
Kityo, C. [1 ]
Hagins, D. [2 ]
Koenig, E. [3 ]
Avihingsanon, A. [4 ]
Chetchotisakd, P. [5 ]
Supparatpinyo, K. [6 ]
Gankina, N. [7 ]
Pokrovsky, V. [8 ]
Voronin, E. [9 ]
Stephens, J. L. [10 ]
DeJesus, E. [11 ]
Wang, H. [12 ]
Acosta, R. [12 ]
Brainard, D. [12 ]
Martin, H. [12 ]
Makadzange, T. A. [12 ]
机构：
[1] Joint Clin Res Ctr, Kampala, Uganda
[2] Chatham Care Ctr, Georgia Dept Publ Hlth, Savannah, GA USA
[3] Inst Dominicano Estudios Virol IDEV, Dr Pineyro 211, Santo Domingo, Dominican Rep
[4] Thai Red Cross AIDS Res Ctr, HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand
[5] Srinagarind Hosp, Khon Kaen, Thailand
[6] Chiang Mai Univ, Chiang Mai, Thailand
[7] Krasnoyarsk Terr Ctr Prevent & Control AIDS & Inf, Krasnoyarsk, Russia
[8] Ctr Prevent & Control AIDS, Moscow, Russia
[9] Republican Clin Infect Hosp, Minist Hlth Russian Federat, Fed State Inst, St Petersburg, Russia
[10] Mercer Univ, Sch Med, Macon, GA 31207 USA
[11] Orlando Immunol Ctr, Orlando, FL USA
[12] Gilead Sci, Foster City, CA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
MOAB0106
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [41] Efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir combinations in HIV-1 adult population: A systematic review and meta-analysis
    Biju, Anto Amith J.
    Shaju, Aina
    Mudigubba, Manoj Kumar
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 325 - 326
  • [42] Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide
    Orkin, Chloe
    Antinori, Andrea
    Rockstroh, Juergen
    Guillen, Santiago Moreno
    Martorell, Claudia
    Molina, Jean-Michel
    Lazzarin, Adriano
    Maggiolo, Franco
    Yazdanpanah, Yazdan
    Andreatta, Kristen
    Huang, Hailin
    Hindman, Jason
    Martin, Hal
    Baeten, Jared
    Pozniak, Anton
    HIV MEDICINE, 2023, 24 : 21 - 22
  • [43] Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials
    Orkin, Chloe
    Ajana, Faiza
    Kityo, Cissy
    Koenig, Ellen
    Natukunda, Eva
    Gandhi-Patel, Bhumi
    Wang, Hui
    Liu, Yapei
    Wei, Xuelian
    White, Kirsten
    Makadzange, Tariro
    Pikora, Cheryl
    McNicholl, Ian
    Collins, Sean E.
    Brainard, Diana
    Chuck, Susan K.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (04) : 393 - 398
  • [44] Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/ emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
    Orkin, Chloe
    DeJesus, Edwin
    Ramgopal, Moti
    Crofoot, Gordon
    Ruane, Peter
    LaMarca, Anthony
    Mills, Anthony
    Van der Cam, Bernard
    De Wet, Joseph
    Rockstroh, Jurgen
    Lazzarin, Adriano
    Rijnders, Bart
    Podzamczer, Daniel
    Thalme, Anders
    Stoeckle, Marcel
    Porter, Danielle
    Liu, Hui
    Cheng, Andrew
    Quirk, Erin
    SenGupta, Devi
    Cao, Huyen
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [45] Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients
    Zhao, Wenjuan
    Liu, Yi
    Zhang, Mengdi
    Cui, Zixin
    Qu, Zhan
    Li, Yiyang
    Wan, Meijuan
    Wang, Wen
    Chen, Yunru
    Shi, Lei
    Li, Jianzhou
    Ye, Feng
    FRONTIERS IN MEDICINE, 2024, 11
  • [46] High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence
    Andreatta, Kristen
    DAntoni, Michelle L.
    Chang, Silvia
    Parvangada, Aiyappa
    Martin, Ross
    Blair, Christiana
    Hagins, Debbie
    Kumar, Princy
    Hindman, Jason T.
    Martin, Hal
    Callebaut, Christian
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (10)
  • [47] LONGER TERM SAFETY OF F/TAF AND F/TDF FOR HIV PREP: DISCOVER TRIAL WEEK 96 RESULTS
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L. C.
    Henry, K.
    Asmuth, D. M.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J. M.
    Kronborg, G.
    Fagan, D.
    Spinner, C. D.
    SEXUAL HEALTH, 2020, 17 (05) : XXII - XXII
  • [48] Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) from a boosted protease inhibitor-based regimen
    Rockstroh, J.
    Molina, J. M.
    Post, F.
    Fox, J.
    Koenig, E.
    Daar, E. S.
    Ruane, P.
    Crofoot, G.
    Oguchi, G.
    Creticos, C.
    Liu, A.
    Andreatta, K.
    Graham, H.
    Brainard, D.
    Martin, H.
    HIV MEDICINE, 2021, 22 : 5 - 5
  • [49] Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: pooled 12-month (12M) results from the global BICSTaR study
    Spinner, C.
    Stoehr, A.
    Wong, A.
    De Wet, J.
    Zeggagh, J.
    Hocqueloux, L.
    Welzen, B. V.
    Heinzkill, M.
    Sahali, S.
    Cornejo, A.
    Ramroth, H.
    Haubrich, R.
    Thorpe, D.
    Lambert, J.
    Kim, C.
    HIV MEDICINE, 2021, 22 : 24 - 24
  • [50] Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: pooled 12-month (12M) results from the global BICSTaR study
    Spinner, Christoph
    Stoehr, Albrecht
    Wong, Alexander
    de Wet, Joss
    Zeggagh, Jeremy
    Hocqueloux, Laurent
    van Welzen, Berend
    Heinzkill, Marion
    Sahali, Sabrinel
    Cornejo, Almudena Torres
    Ramroth, Heribert
    Haubrich, Richard
    Thorpe, David
    Kim, Connie
    INFECTION, 2021, 49 (SUPPL 1) : S16 - S16
12345